A5016278612- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Epigenetics and DNA Methylation
- Peptidase Inhibition and Analysis
- Ferroptosis and cancer prognosis
- Erythrocyte Function and Pathophysiology
- Methemoglobinemia and Tumor Lysis Syndrome
- Immune cells in cancer
- Trauma and Emergency Care Studies
- Injury Epidemiology and Prevention
- Burn Injury Management and Outcomes
- Neonatal Health and Biochemistry
Children's Hospital of Zhejiang University
2025
Anhui Medical University
2024
Impacts of red blood cell (RBC) suspension storage on outcomes in pediatric patients receiving RBC transfusions remains uncertain. Therefore, our objective is to examine the association between duration and patients. A retrospective study was conducted 222 admitted medical surgical departments at center 2021. Primary assessed were 28-day mortality length hospital stays, while secondary included transfusion-related complications, total volume transfusions, number interval transfusions....
Currently, only 20-40% of cancer patients benefit from immune checkpoint inhibitors. Understanding the mechanisms underlying immunosuppressive tumor microenvironment (TME) and characterizing dynamic changes in immunological landscape during treatment are critical for improving responsiveness to immunotherapy. Here, we identified JNK signaling cancer-associated fibroblasts (CAFs) as a regulator microenvironment. Single-cell RNA sequencing bladder treated with inhibitor revealed enhanced...
Objective: To analyze the epidemiological characteristics of hospitalized children with severe burn from several regions in China during 3 years, so as to provide evidence for prevention burns children. Methods: Relying on entry system epidemiology data and biological sample multicenter clinic, medical records burn, aged 18 under, 6 wards February 2012 2015 were collected. The divided into 5 age brackets: less than or equal 1 year old, more old years 12 old. Meanwhile rural urban according...
<p>Supplementary Figures 1-8</p>
<div>Abstract<p>Currently, only 20% to 40% of patients with cancer benefit from immune checkpoint inhibitors. Understanding the mechanisms underlying immunosuppressive tumor microenvironment (TME) and characterizing dynamic changes in immunologic landscape during treatment are critical for improving responsiveness immunotherapy. In this study, we identified JNK signaling cancer-associated fibroblasts (CAF) as a regulator TME. Single-cell RNA sequencing bladder samples treated...